Clinical Trials | June 02, 2026
BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
The safety profile was described as manageable, though not without notable toxicities
The safety profile was described as manageable, though not without notable toxicities
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Pharma giant targets new standards of care
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Subscribe To Our Newsletter & Stay Updated
